Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AZ gets US and Canadian rights to Actavis' branded respiratory portfolio

Executive Summary

AstraZeneca PLC will pay $600mm up front, plus low-single-digit royalties, to acquire rights to Actavis PLC’s branded respiratory drug portfolio in the US and Canada. AZ will also hand over $100mm related to undisclosed contractual consents and approvals pertaining to previous collaborations with Actavis.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies